Emerging biotherapies for Sjögren's syndrome

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Expert Opinion on Emerging Drugs

• Publication date

  2010-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14728211003702392PMID 20384543
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulation of Adaptive Immunity by the Innate Immune System

  2010cited by this paper
• Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.

  2010cited by this paper
• Ectopic Germinal Centers Are Rare in Sjögren’s Syndrome Salivary Glands and Do Not Exclude Autoreactive B Cells1

  2009cited by this paper
• Efficacy and safety of infliximab in active SLE: a pilot study

  2009influential reference
• B lymphocyte cytokines and rheumatic autoimmune disease.

  2009cited by this paper
• Tumor Necrosis Factor Inhibitors Block Apoptosis of Human Epithelial Cells of the Salivary Glands

  2009cited by this paper
• Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome.

  2009cited by this paper
• Treatment of primary Sjögren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment

  2009cited by this paper
• Use of rituximab in patients with systemic lupus erythematosus: an update.

  2009cited by this paper
• New ELISA for B cell-activating factor.

  2009cited by this paper
• Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence.

  2009cited by this paper
• Should Rituximab be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases?

  2008cited by this paper
• BAFF, APRIL, TWE-PRIL: who's who?

  2008cited by this paper
• Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study

  2008cited by this paper
• Resistance to Rituximab Therapy and Local BAFF Overexpression in Sjögren’s Syndrome-Related Myoepithelial Sialadenitis and Low-Grade Parotid B-Cell Lymphoma

  2008cited by this paper
• Editing Antigen Presentation: Antigen Transfer between Human B Lymphocytes and Macrophages Mediated by Class A Scavenger Receptors1

  2008cited by this paper
• Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

  2008influential reference
• BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?

  2008cited by this paper
• B‐cell‐activating factor inhibits CD20‐mediated and B‐cell receptor‐mediated apoptosis in human B cells

  2008cited by this paper
• Emerging Biological Therapies in Systemic Lupus Erythematosus

  2008cited by this paper
• [B lymphocytes in Sjögren's syndrome].

  2008cited by this paper
• New therapies for treatment of rheumatoid arthritis.

  2007cited by this paper
• BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.

  2007cited by this paper
• A case for B cells in the pathogenesis of Sjögren's syndrome

  2007cited by this paper
• Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome.

  2007cited by this paper
• Polarization of B effector cells in Sjögren's syndrome.

  2007cited by this paper
• B cell conducts the lymphocyte orchestra.

  2007cited by this paper
• Ultrasound assessment of salivary glands in patients with primary Sjögren’s syndrome treated with rituximab: Quantitative and Doppler waveform analysis

  2007cited by this paper
• Depletion of B Cells in Murine Lupus: Efficacy and Resistance1

  2007cited by this paper
• Extranodal marginal zone B-cell lymphoma of the lung in Sjögren's syndrome patients: reappraisal of clinical, radiological, and pathology findings.

  2007cited by this paper
• Update on Sjögren's syndrome autoimmune epithelitis: from classification to increased neoplasias.

  2007cited by this paper
• Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.

  2007influential reference
• Sjögren’s Syndrome or Autoimmune Epithelitis?

  2007cited by this paper
• Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20).

  2007cited by this paper
• BAFF synthesis by rheumatoid synoviocytes is positively controlled by alpha5beta1 integrin stimulation and is negatively regulated by tumor necrosis factor alpha and Toll-like receptor ligands.

  2007influential reference
• Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome

  2006cited by this paper
• Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases

  2006cited by this paper
• Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

  2006cited by this paper
• BAFF-induced changes in B cell antigen receptor-containing lipid rafts in Sjögren's syndrome.

  2006cited by this paper
• CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction.

  2005cited by this paper
• Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism.

  2005cited by this paper
• Sjögren's syndrome.

  2005cited by this paper
• Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.

  2005cited by this paper
• Interferon alfa treatment for Sjögren’s syndrome associated neuropathy

  2005cited by this paper
• BAFF Overexpression Is Associated with Autoantibody Production in Autoimmune Diseases

  2005cited by this paper
• Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

  2004cited by this paper
• Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

  2004cited by this paper
• TNF Deficiency Fails to Protect BAFF Transgenic Mice against Autoimmunity and Reveals a Predisposition to B Cell Lymphoma1

  2004cited by this paper
• The BLyS family of ligands and receptors: an archetype for niche‐specific homeostatic regulation

  2004cited by this paper
• Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.

  2004cited by this paper
• Circulating Cytokines in Primary Sjögren's Syndrome Determined by a Multiplex Cytokine Array System

  2004cited by this paper
• Treatment of B-cell lymphoma with rituximab in two patients with Sjögren's syndrome associated with hepatitis C virus infection.

  2004cited by this paper
• Laboratory testing in autoimmune rheumatic diseases.

  2004influential reference
• Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).

  2004cited by this paper
• Clinical manifestations and early diagnosis of Sjögren syndrome.

  2004cited by this paper
• Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study.

  2004cited by this paper
• Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma.

  2003cited by this paper
• Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells.

  2003cited by this paper
• Tumor Necrosis Factor Inhibitor Gene Expression Suppresses Lacrimal Gland Immunopathology in a Rabbit Model of Autoimmune Dacryoadenitis

  2003cited by this paper
• A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.

  2003cited by this paper
• Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results.

  2003cited by this paper
• The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren’s syndrome

  2003cited by this paper
• Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor.

  2003cited by this paper
• Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator.

  2003cited by this paper
• Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome.

  2002influential reference
• Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome.

  2002cited by this paper
• F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: before and after anti-CD20 antibody rituximab therapy.

  2002influential reference
• BAFF: A fundamental survival factor for B cells

  2002cited by this paper
• The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren’s syndrome

  2002cited by this paper
• Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group

  2002cited by this paper
• Genetic profiling versus drug rotation in the optimisation of antihypertensive treatment.

  2002cited by this paper
• Infliximab in primary Sjögren's syndrome: one-year followup.

  2002cited by this paper
• The molecular basis of lymphoid architecture and B cell responses: implications for immunodeficiency and immunopathology.

  2001cited by this paper
• Infliximab in patients with primary Sjögren's syndrome: a pilot study.

  2001cited by this paper
• Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

  2001cited by this paper
• Sjögren’s syndrome: current therapies remain inadequate for a common disease

  2000cited by this paper
• Sjögren's syndrome. Autoimmune epithelitis.

  2000cited by this paper
• Reciprocal regulation of polarized cytokine production by effector B and T cells

  2000cited by this paper
• Deficiency in CD22, a B Cell–specific Inhibitory Receptor, Is Sufficient to Predispose to Development of High Affinity Autoantibodies

  1999cited by this paper
• Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome.

  1999influential reference
• Treatment of Primary Sjogren's Syndrome with Low-Dose Natural Human Interferon-alpha Administered by the Oral Mucosal Route: A Phase II Clinical Trial

  1999cited by this paper
• Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations

  1999influential reference
• BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth

  1999cited by this paper
• Single-Blinded Controlled Trial of Low-Dose Oral IFN-α for the Treatment of Xerostomia in Patients with Sjögren's Syndrome

  1998cited by this paper
• Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

  1998influential reference
• Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome.

  1998cited by this paper
• Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjögren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine.

  1996cited by this paper
• CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice.

  1996cited by this paper
• Sjögren's syndrome

  1995cited by this paper
• CD20: a regulator of cell-cycle progression of B lymphocytes.

  1994cited by this paper
• Sjögren's syndrome: autoimmune epithelitis.

  1994cited by this paper
• The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes.

  1993cited by this paper
• IgA-containing immune complexes in the circulation of patients with primary Sjögren's syndrome.

  1991cited by this paper
• Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C.

  1989cited by this paper
• Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.

  1988cited by this paper
• Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas.

  1987cited by this paper
• The B cell surface molecule B1 is functionally linked with B cell activation and differentiation.

  1985cited by this paper
• Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation.

  1984cited by this paper
• Immune interferon in the circulation of patients with autoimmune disease.

  1979cited by this paper
• Sj??gren??s syndrome

  1975cited by this paper

• Syndrome de Gougerot-Sjögren primitif

  2020cites this paper
• Síndrome de Sjögren primario

  2020cites this paper
• Epigenetic modifications affect cytokeratin 19 expression in salivary glands from patients with Sjögren's syndrome.

  2016cites this paper
• Allogenic banking of dental pulp stem cells for innovative therapeutics.

  2015cites this paper
• Topical biological agents targeting cytokines for the treatment of dry eye disease

  2013cites this paper
• 50 – Sjögren syndrome

  2013cites this paper
• In Sjögren's syndrome, B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation.

  2012cites this paper
• Implication des lymphocytes B et de BAFF dans l'apoptose des cellules épithéliales des glandes salivaires au cours du syndrome de Gougerot-Sjögren

  2012cites this paper
• Syndrome de Sjögren primitif

  2012cites this paper
• Síndrome de Sjögren primario

  2012cites this paper
• Experimental Therapies in Sjögren’s Syndrome

  2011cites this paper
• Primary Sjögren’s syndrome: current pathophysiological, diagnostic and therapeutic advances

  2011cites this paper
• [B-cell depletion and primary Sjögren's syndrome: is there a role for rituximab?].

  2011cites this paper
• Skin biopsy as a routine diagnostic tool for primary Sjögren’s syndrome

  2011cites this paper
• Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases.

  2011cites this paper
• The international symposium on Sjögren's syndrome in Brest: the "top of the tops" at the "tip of the tips".

  2010cites this paper
• Conference scene: Highlights of the 7th Autoimmunity Congress.

  2010cites this paper